KRASᴳ¹²ᶜ-Mutant NSCLC: Biology, Developmental Therapeutics, and Molecular Testing

2021 Year in Review - Non–Small-Cell Lung Cancer - Lung Cancer

KRAS is the most prevalent oncogenic driver in advanced non–small-cell lung cancer (NSCLC), which occurs in approximately 30% of patients with lung adenocarcinomas. More than 80% of oncogenic KRAS mutations occur at codon 12, where various amino acids replace the glycine residue, resulting in genomic heterogeneity in KRAS mutation–positive cancers. The KRAS glycine-to-cysteine mutation (G12C), or KRASG12C, accounts for more than 44% of KRAS mutations in NSCLC, with mutant KRASG12C seen in approximately 13% of all patients with lung adenocarcinomas.1

KRAS is a protein that belongs to the RAS GTPase family. Extracellular stimuli such as growth factors activate KRAS, which leads to the activation of downstream signaling pathways that regulate cell proliferation, migration, survival, and differentiation.1 This is the mechanism whereby KRAS stimulates cancer cell proliferation and tumor growth.1

Despite more than 4 decades of research, KRAS has remained an untreatable target. The KRAS wild-type protein lacks surface pockets large enough to allow tiny molecules to bind and hinder its function. As a result of the high affinity of guanosine triphosphate for KRAS, competitive inhibition of KRAS wild-type has proved difficult. Toxicity from nonselective interaction with KRAS wild-type has hindered other techniques to targeting KRAS.1

Sotorasib, a first-in-class KRAS inhibitor has recently received accelerated approval by the US Food and Drug Administration (FDA) for the treatment of adult patients with KRASG12C mutation–positive, locally advanced or metastatic NSCLC who have received ≥1 previous systemic therapies.2

KRAS mutations are not directly predictive for therapy management until more viable KRAS-directed therapies are approved. The current expert agreement on employing molecular testing to determine targeted tyrosine kinase inhibitor treatment does not advocate KRAS mutation testing as a standard stand-alone test. If no mutations in EGFR, ALK, or ROS1 are found, or if KRAS is part of a broader multigene panel, KRAS testing can be done.1 As a result, it is not unexpected that rates of testing for EGFR and ALK mutations range from 38% to 91%. KRAS mutations ranged from 0% to 28%. Given the recent success in the development of KRAS-directed therapies such as sotorasib, molecular testing is becoming more important for identifying patients with KRAS mutations (eg, KRASG12C) who might be candidates for these innovative medicines. As a result, practitioners must be made aware of the benefits of having KRAS mutation testing in their pretreatment molecular testing list, as well as the importance of testing for KRASG12C mutations.1

References

  1. Veluswamy R, Mack PC, Houldsworth J, et al. KRAS G12C–mutant non–small cell lung cancer: biology, developmental therapeutics, and molecular testing. J Mol Diagn. 2021;23:507-520.
  2. Amgen. FDA approves Lumakras (sotorasib), the first and only targeted treatment for patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer. May 28, 2021. www.amgen.com/newsroom/press-releases/2021/05/fda-approves-lumakras-sotorasib-the-first-and-only-targeted-treatment-for-patients-with-kras-g12cmutated-locally-advanced-or-metastatic-nonsmall-cell-lung-cancer. Accessed December 9, 2021.
Related Items
Third-Line Tyrosine Kinase Inhibitor Therapy Results in 16-Year Remission in a Patient with Stage IV Non–Small-Cell Lung Cancer
JHOP - August 2022 Vol 12, No 4 published on August 22, 2022 in Case Reports, Lung Cancer
2022 Midyear Review: Non–Small-Cell Lung Cancer
JHOP - Supplements published on July 21, 2022 in Lung Cancer
First-Line Sotorasib Shows Long-Lasting Responses in Metastatic NSCLC with KRAS Mutation
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in AACR Highlights, Lung Cancer
Opdivo plus Platinum-Based Chemotherapy FDA Approved as First Neoadjuvant Treatment in Early-Stage NSCLC
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update, Lung Cancer, Checkpoint Inhibitors
Severe Adverse Events from Immune Checkpoint Inhibitor Therapy a Rare Concerning Side Effect
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
KRASᴳ¹²ᶜ Mutation–Positive Advanced NSCLC
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
CodeBreaK 100 Trial Results Demonstrate Sotorasib Conveys Clinical Benefit Across NSCLC Patient Subgroups
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
NSAID Use with Immune Checkpoint Inhibitors Associated with Longer Overall Survival in NSCLC
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
The Effect of Various KRAS Mutations on NSCLC Susceptibility
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
Patterns of Biomarker Testing in Metastatic NSCLC in the Community Oncology Setting
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: